Amylin [AMLN] just inked an agreement with Nastech [NSTK] another of my investments that calls for Nastech to develop a nasal version of Amylin's Byetta drug. It's a no-brainer that patients will prefer a sniff to an injection.
In the interests of full disclosure, Nastech is my biggest position. I have had a position in the stock for over six years. |
Logged
